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Background: The MDM2 gene is the major negative regulator of p53, a tumor suppressor protein. Single nucleotide
polymorphism in promoter region of MDM2 gene leads to increased expression resulting in higher levels of MDM2
protein. This event increases the attenuation of the p53 pathway. Polymorphisms in this gene can interfere in the
regulation of cellular proliferation. We evaluated whether MDM2 SNP309 (rs2278744) associated or not with the use
of oral contraceptive can heighten susceptibility to development of cervical lesions in women HPV infected.
Methods: MDM2 SNP309 (rs2278744) was genotyped in a total of 287 patients using the PCR-RFLP technique. The
results were analyzed by UNPHASED v.3.121 and SNPStats programs.
Results: The three groups (SIL, LSIL and HSIL) showed no significant differences in either genotype or allelic frequencies
for MDM2 polymorphisms, except when HSIL was compared with LSIL (p = 0.037; OR = 1.81). Furthermore, in the analysis
of contraceptives, a significant association was found between the use of contraceptives and the MDM2 variant in the
development of high-grade cervical lesions for the TG genotype (p = 0.019; OR = 2.21) when HSIL was compared with
control. When HSIL was compared with LSIL (p = 0.006; OR = 2.27).
Conclusion: The results of this study suggest that MDM2 SNP309 might be a good marker for assessing the progression
of LSIL to HSIL. In addition, they also show that oral contraceptives alone, did not have any effect on the progression or
development of cervical lesions. However, they may act synergistically with MDM2 SNP309 (rs2278744) and HPV
infection in the development of cervical lesions.
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Cervical cancer is the third most frequent cancer and
the second most common cause of death among women
worldwide [1]. Its prevalence is especially high in devel-
oping countries, which account for 86% of all cases [1].
In Brazil, there are more than 17,500 new cases every
year and 4,812 deaths [2]. Currently, the main screening
method for cervical cancer is the Papanicolau (Pap)* Correspondence: acf_ufpe@yahoo.com.br
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unless otherwise stated.smear test which is based on an analysis of cervical cell
morphology. The cervical cancer precursor is the squa-
mous intraepithelial lesion (SIL) that may be either a high
squamous intraepithelial lesion (HSIL) or a low squamous
intraepithelial lesion (LSIL) [3].
It is well established that the major etiological factor in
cervical cancer is Human papillomavirus (HPV) infection
[4,5]. HPV DNA is detected in over 95% of the cases of
invasive cervical cancer worldwide [6]; however, the type
of HPV, as well as genetic and environmental factors,
can influence the persistence of HPV infection and the
progression of lesions to cervical cancer [7-9]. The useLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in the development of cervical cancer and in making
the user predisposed to the disease [9]. It is believed
that steroids hormones interact with a specific DNA se-
quences on transcriptional regulatory sites on the HPV
DNA increasing or suppressing the transcription of
various genes [10]. Estradiol and progesterone can be
responsible for modulation the host genes that are in-
volved in immune response to HPV16 [11]. Moreover,
the association with cervical cancer depends the type-
specific HPV infection [12]. The effects of oral contra-
ceptive on cervical cancer are transient because the
association increases with duration of use [13,14] and
decreases after discontinuation [11,13,14].
The HPV E6 oncoprotein that is involved in cervical
cancer makes use of the cellular ubiquitin–protein ligase
E6-AP to target the p53 transcription factor for degrad-
ation [15]. The human homolog of mouse double minute
2 (mdm2) protein is the main negative regulator of the
p53 function [16]. Mdm2 targets the p53 protein by
ubiquitination for its degradation and suppresses p53 by
inhibiting its trans-activation function [17]. The level of
p53 is regulated through an auto-regulatory feedback loop
where p53 induces the transcription of MDM2.
The MDM2 regulation of disorders is associated with
the development of cancer, which is confirmed by the
evidence that MDM2 was over-expressed in some human
cancers [18,19]. MDM2 single nucleotide polymorphism
SNP (rs2279744) has already been described as being
associated with several types of cancer [20,21], and also
with accelerated tumorigenesis and poor prognosis
[22]. This polymorphism is located in position 309 in
the first intron of the MDM2 oncogene, which serves
as a transcriptional enhancer region. When T is replaced
with G, this increases the affinity of the Sp1 transcription
factor and it has been shown that cells carrying the
T309G genotype have a 2-3-fold increase in MDM2
mRNA and protein synthesis. This leads to the abrogation
of p53 tumor suppressor activity and the development of
cancer [23].
Our study sought to determine whether the presence of
polymorphism in the MDM2 gene associated or not with
the use of oral contraceptives can heighten susceptibility
to the development of cervical lesions in women HPV
infected.
Results
This study was conducted with 212 cases of cervical
lesions from North-East Brazil who underwent cervical
cancer screening and 75 individuals that does not have
lesions acting as a control group.
The age of the patients included in the current study
ranged from 15–77 the average age being 33 and the
mean was at 34.02 + 11.05 years. In accordance with theirHPV types, 78% of all the patients were infected with
high-risk HPV against 22% that were infected with
low-risk. In the control group, 65% were infected
with high-risk HPV and 35% with low-risk HPV. In
the LSIL group, 74% were infected with high-risk HPV
and 26% with low-risk HPV. In the HSIL group, 98%
were infected with high-risk HPV and 2% with low-risk.
The SNP were evaluated in compliance with the Hardy-
Weinberg principle. The frequencies of each allele and
genotype are given in Table 1.
Patients with both LSIL and HSIL were included in the
SIL group. The three groups (SIL, LSIL and HSIL) showed
no significant differences in either genotype or allelic
frequencies for MDM2 SNP309 polymorphism, except
when HSIL was compared with LSIL for the MDM2
gene. The difference was significant (p = 0.037; OR = 1.81,
95% CI 1.03-3.16) with regard to the TG genotype when
TT was used as a reference-point. This showed that the
significant genetic model was over-dominant, with the
heterozygote being at a greater risk of evolution of LSIL
for HSIL than either of the homozygotes. Although this is
a no intuitive model, there is a precedent for other genes
acting in this manner (see Discussion).
An examination was carried out to establish the possible
influence of the use of hormonal contraceptives on the
susceptibility of women to the development of cervical
lesions (Table 2). There was no association between the
use of contraceptives and LSIL and HSIL.
Another examination was carried out to establish the
effects of the use of hormonal contraceptives (together
with variants of the MDM2 gene) on the development of
cervical lesions (Table 3). When the TT-GG genotypes
were used as a reference-point, a significant difference
was found between HSIL and the control groups [p < 0.05;
OR = 2.21 (1.13-4.30)] and the TG genotype, for MDM2
SNP309. A significant difference was also found in the TG
genotype when HSIL was compared with LSIL. The risk
ranged from 2.01 to 2.31 depending on the model used.
For codominant model, the risk was 2.31; for dominant
model, the risk was 2.01 and for overdominant model, the
risk was 2.27 to TG genotype. Since the overdominant
model was the most significant (p = 0.006). We also com-
pared MDM2 SNP309 allele distribution among oral
contraceptive users and non-users between the three
groups, LSIL, HSIL and normal cytology (Table 4).
Discussion
In this study, we evaluated whether MDM2 SNP309
(rs2278744) associated or not with the use of oral contra-
ceptive can heighten susceptibility to development of
cervical lesions.
The nature of the relationship between MDM2 SNP309
(rs2278744) and cervical cancer is not clear. There have
been few studies in this area and the conclusions are
Table 1 MDM2 (rs2278744) polymorphism in patients with HPV and cervical lesions of low degree (LSIL) and high
degree (HSIL) and healthy patients
Cases Normal cytology p-value; OR [95% C.I.]
Total SILa LSILb HSILc Controld Total SIL vs. C LSIL vs. C HSIL vs. C HSIL vs. LSIL
SNP309 rs2278744
Alelles
T 265 (0.62) 165 (0.63) 100 (0.61) 95 (0.63) Reference Reference Reference Reference









TT 80 (0.37) 54 (0.42) 26 (0.30) 30 (0.40) Reference Reference Reference Reference
















p < 0.05 – statistically significant.
aSIL: Squamous intraepithelial lesions.
bLSIL: Low-grade squamous intraepithelial lesions.
cHSIL: High-grade squamous intraepithelial lesions.
dC: Control - Normal cytology.
*In overdominant model the risk to TG genotype was 1.81 (1.03-3.16, 95% CI).
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frequency of MDM2 SNP309 (rs2278744) allele and
genotype were not significant between the LSIL and
HSIL groups, when compared with the control group.
This is consistent with the results of a single study
with a Brazilian population that was carried out to test
whether MDM2 SNP309 (rs2278744) was associated
with either the risk of cervical cancer or its diagnosis at an
early age. In this study, Meissner et al. [24] compared 72
cervical carcinoma patients with 100 healthy patients and
no association was observed between MDM2 SNP309
(rs2278744) and cervical cancer. Our results lend weight
to the conclusions of Meissner et al. [24] that MDM2
SNP309 (rs2278744) may not be a risk factor for the
development of cervical carcinogenesis.
However, our study found a statistically significant result
of this SNP with the progression of LSIL to HSIL, which
was not analyzed by Meissner et al. [24]. In contrast,
recently, Singhal et al. [25] found association betweenTable 2 Distribution of use of contraceptive according to the
Cases Normal cy
Total SILa LSILb HSILc Contro
Variable
Use of contraceptive
No 167 (0.68) 109 (0.65) 58 (0.75) 55 (0.6
Yes 78 (0.32) 95 (0.35) 19 (0.25) 25 (0.3
p < 0.05 – statistically significant.
aSIL: Squamous intraepithelial lesions.
bLSIL: Low-grade squamous intraepithelial lesions.
cHSIL: High-grade squamous intraepithelial lesions.
dC: Control - Normal cytology.higher frequency of G allele and cervical cancer in Indian
women infected with HPV. In the study of a population in
China, involving 167 cervical cancer and 223 controls,
Jiang et al. [26] found an increased risk of cervical can-
cer associated with MDM2 SNP309 (rs2278744) GG.
Nunobiki et al. [27] investigated whether or not the
combination of MDM2 SNP309 (rs2278744) with HPV
types could be associated with cervical lesions and
cancer. Their study consisted of 102 LSIL, 41 HSIL and 52
normal (controls). MDM2 SNP309 (rs2278744) was found
to be associated with cervical carcinogenesis especially in
the high-risk HPV group.
The divergence between the findings of these studies
and the present study might be caused by racial, ethnic
or samples differences in the populations studied, since
in our study we worked with pre-cancerous lesions.
According to a study carried out by Wo et al. [28], in
the case of an Asian population, the mean frequency of
309G is 0.49 and 0.36 for the mixed population. ItSIL, LSIL, HSIL and controls
tology p-value; OR [95% C.I.]
ld Total SIL vs. C LSIL vs. C HSIL vs. C HSIL vs. LSIL








2) p = 1.0 p = 0.66 p = 0.37 p = 0.10
Table 3 MDM2 (rs2278744) polymorphisms in patients with HPV and cervical lesions of low degree (LSIL) and high
degree (HSIL) and healthy patients with contraceptive as co-factor
Cases Normal cytology p-value; OR [95% C.I.]
Total SILa LSILb HSILc Controld Total SIL vs. C LSIL vs. C HSIL vs. C HSIL vs. LSIL
SNP309 rs2278744
Alelles
T 254 (0.61) 165 (0.63) 89 (0.59) 92 (0.64) Reference Reference Reference Reference









TT 74 (0.36) 54 (0.41) 20 (0.26) 30 (0.42) Reference Reference Reference Reference
















p-value adjusted with contraceptive.
p < 0.05 – statistically significant.
aSIL: Squamous intraepithelial lesions.
bLSIL: Low-grade squamous intraepithelial lesions.
cHSIL: High-grade squamous intraepithelial lesions.
dC: Control - Normal cytology.
1In overdominant model the p-value was 0.019; OR = 2.21 (95% CI, 1.13-4.30).
2In dominant model the p-value was 0.02; OR = 2.01 (95% CI, 1.07-3.76) and in overdominant model, the p-value was 0.006; OR = 2.27 (95% CI, 1.25-4.10).
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differences found in this study in greater depth.
When HSIL was compared with LSIL, the difference
was significant and showed a risk of 1.81 with the TG
genotype when the TT-GG genotype was used as a
reference-point (overdominant model). The genetic model
suggested by this data appears to be an over-dominant
protective effect of MDM2. This model is also called
‘heterozygote disadvantage’, and although it may appear
counterintuitive, a review suggests that this mode of
action is perhaps more common than previously thought
and cites numerous examples [29]. Indeed, the MDM2
promoter polymorphism has been associated with the
severity of HPV, and this also seems to follow a pattern
of heterozygote disadvantage.Table 4 Comparison MDM2 SNP309 allele distribution among
HSIL and normal cytology (control)
Cases
SNP 309 rs2278744 Total SILa LSILb
Alleles Yes No Total Yes No
T 79 (0.58) 175 (0.63) 254 (0.61) 56 (0.57) 109 (0.68)
G 57 (0.42) 101 (0.37) 158 (0.39) 42 (0.43) 53 (0.32)
Genotypes
TT 22 (0.32) 52 (0.38) 74 (0.36) 17 (0.35) 37 (0.46)
TG 35 (0.51) 71 (0.51) 106 (0.51) 22 (0.45) 35 (0.43)
GG 11 (0.17) 15 (0.11) 26 (0.13) 10 (0.20) 9 (0.11)
aSIL: Squamous intraepithelial lesions.
bLSIL: Low-grade squamous intraepithelial lesions.
cHSIL: High-grade squamous intraepithelial lesions.
dControl: Normal cytology.According to the MDM2 polymorphism (SNP309) ana-
lysis, our study reported that there is a small discrepancy
between control and LSIL groups. However, this differ-
ence is considerable between LSIL and HSIL groups. This
suggest that MDM2 SNP309 may be a good marker to
assess the progression of LSIL to HSIL. More studies
should be done to continue this hypothesis.
We also examined the role of contraceptives as an
environmental co-factor in the risk of cervical lesions. Some
studies did not observe any association between the use of
oral contraceptives and cervical lesions [30-32]. However,
several studies demonstrated that when combined with
other factors the history of the use of contraceptives
affects the development of cervical lesions, and the risk is
increased with the duration of their use [33-36]. In ouroral contraceptive users and non-users between LSIL,
Controld
HSILc
Total Yes No Total Yes No Total
165 (0.63) 23 (0.60) 66 (0.58) 89 (0.59) 29 (0.60) 63 (0.66) 92 (0.64)
95 (0.37) 15 (0.40) 48 (0.42) 63 (0.41) 19 (0.40) 33 (0.34) 52 (0.36)
54 (0.41) 5 (0.26) 15 (0.27) 20 (0.26) 9 (0.37) 21 (0.44) 30 (0.42)
57 (0.44) 13 (0.69) 36 (0.63) 49 (0.64) 11 (0.46) 21 (0.44) 32 (0.44)
19 (0.15) 1 (0.05) 6 (0.10) 7 (0.10) 4 (0.17) 6 (0.12) 10 (0.14)
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or together with MDM2 SNP309 in women with HPV
infection. No association was found when the use of
contraceptives was evaluated alone. This finding was
consistent with the results of Castle et al. [32], who did
not find a higher risk of high-grade lesions or cervical
cancer among 1160 women who used contraceptives
compared with 2094 who did not use them. Hildesheim
et al. [31] did not find oral contraceptives had an effect
on cervical lesions when this co-factor was evaluated
alone. Deacon et al. [30] observed that the use of oral
contraceptives was not significantly associated with
high-grade lesions. When comparing 211 HSIL and 1475
invasive cancer patients with 255 HPV- positive controls
without lesions, Moreno et al. [35] found that those
who had used contraceptives for less than 5 years did
not demonstrate an increased risk of cervical cancer.
Nevertheless, the risk increased 2.82- fold when the use
was over a period of 5–9 years and 4.03- fold when the use
lasted for 10 years or more. Brisson et al. [34] observed a
relative 1.9 risk of high-grade lesions in patients that had
used contraceptives for 6 years or more compared with
those who never used them. Briton et al. [33], found that
the risk was two-fold for users of 5 or more years. A studyFigure 1 Representative genotypes of MDM2 SNP (rs2278744). MDM2
fragment (Columns 1,9), homozygous GG produced 2 fragments of 104 bp
heterozygot TG produced 3 fragments of 121 bp, 104 bp and 17 bp (Colunconducted by Luhn et al. [36] with 2783 women in various
stages of cervical disease, showed that long-term oral
contraceptive use (a period of more than 10 years) was
associated with HSIL with the risk being 2.42- fold
higher than those that had never used contraceptives.
These results are in contrast with the current study
where the use of contraceptives alone was not associated
with development of cervical lesions. Factors such as the
discontinuous use of contraceptives and the duration of
their use can explain this divergence. It is also possible
that in studies where associations were found between
the use of contraceptives and development of lesions
and cervical cancer, there is also an interaction with the
host genetic factors which were not analyzed.
When the use of contraceptives was examined with
the presence of MDM2 SNP309 in the development of
cervical lesions, a risk of 2.21 was found in patients with
HSIL and TG genotype when compared with control
and MDM2 MDM2 SNP309. When HSIL was compared
with LSIL, the risk was 2.31 (codominant model), 2.01
(dominant model) and 2.27 (overdominant model). These
results provide clues that contraceptives can act synergis-
tically by increasing susceptibility to the development of
high-grade cervical lesions. According to Bond and LevineSNP (rs2278744) - Wild-type homozygous TT produced a single 121 bp
and 17 bp, which was not detected on the gel (Colunms 2,5,6,7,8) and
ms 3,4).
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the presence of SNP309, the basal levels of the MDM2 in
the cell are elevated, due to the affinity binding site of the
transcription factor Sp1 created in the promoter region.
As a result, the levels of p53 are reduced and the carriers
of the G allele have a low cellular stress response. Thus,
the activated estrogen signaling pathway is necessary for
the G allele to accelerate the formation the tumor [37].
This is the first study that showed an association
between the use of contraceptives and MDM2 SNP309
(rs2278744) in the development of cervical lesions of
women HPV infected. The findings corroborate the hy-
pothesis that the use of contraceptives may be a co-factor
together with HPV infection and MDM2 polymorphism
in the development of cervical lesions.
These findings reported thatMDM2 SNP309 (rs2278744)
were significantly associated with women HPV infected that
using oral contraceptive, suggesting that contraceptives
act together with MDM2 SNP309 (rs2278744) and HPV
infection in the development of cervical lesions in women
HPV infection. Additional studies should be conducted in
order to prove that the polymorphism in MDM2 gene
may come to be used as a marker of the evolution of high
grade lesions in women HPV infected.Figure 2 Sequence analysis. Comparisons of the three genotypes on the si
GG. C – Heterozygous TG.Methods
Ethics statement
The study was approved by the "Research Ethics Com-
mittee of University of Pernambuco", Brazil, (HUOC/
PROCAPE 64/2010) and was approved by the institu-
tional review board of the University Hospital Oswaldo
Cruz. All patients provided written informed consent
prior to collection of sample. It was obtained informed
written consent from the next of kin, caretakers, or
guardians on behalf of the minors that were enrolled in
this study.
Studied subjects
The cervical smears were obtained from 287 patients
from North-East Brazil who volunteered to take part in
cervical cancer screening. All the samples included in
this study were HPV positive. The control group consisted
of 75 patients without cervical lesions and the case group
consisted of 212 patients with cervical lesions which
was divided into LSIL (130 - Low grade squamous intrae-
pithelial lesions) and HSIL (82 - High grade squamous
intraepithelial lesions). The patients signed a consent form
that was approved by the ethics committee of the univer-
sity (HUOC/PROCAPE 64/2010).te of nucleotide change. A – Wild-type homozygous TT. B – Homozigous
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After being collected, the samples were placed in poly-
ethylene tubes containing phosphate-buffered saline
and stored at −20°C for further processing. DNA was
extracted using the DNeasy Blood and Tissue Kit (Qiagen,
São Paulo/Brazil) in accordance with the manufacturer's
instructions.
HPV detection
PCR was used for HPV DNA detection and involved
the amplification of the viral L1 gene fragment using
degenerated primers (MY09/MY11) [38,39]. The primer
sequences were MY09- CGTCCMARRGGAWACTGATC
and MY11- GCMCAGGGWCATAAYAATGG.
MDM2 SNP (rs2279744) genotyping
A Primer- Introduced Restriction Analysis PCR (PIRA-
PCR) assay was used for the genotyping of MDM2
SNP309. This method is based on sense and antisense-
primers, where there is a mismatch of the nucleotide
close to a polymorphic site, which is introduced to create
a restriction site. The antisense-primer introduced
A to replace G at 2 bp from the polymorphic site to
create a PstI restriction site. The primer sequences
were 5’-GATTTCGGACGGCTCTCGCGGC-3’ (sense)
and 5’-CATCCGGACCTCCCGCGCTG-3’ (antisense)
[40]. 50 ng of the DNA template from each sample was
amplified with 0.1 mM dNTP, 1X Taq reaction buffer,
1 mM MgCl2, 0.8 μM of each primer and 1U Taq DNA
polymerase in a final volume of 25 μL. The amplification
reaction was carried out under the following conditions:
95°C for 5 minutes for the initial denaturation of the
genomic material, 35 cycles of 95°C for 30 seconds
(denaturation), 66.5°C for 40 seconds (annealing), 72°C
for 45 seconds (extension) for the amplification of the
gene segment of interest and a cycle of 72°C for 10 minutes
in the final extension of the fragment. The 121 bp PCR
fragment was then digested for 16 hours by 5U PstI
(Invitrogen, São Paulo/Brazil). The wild-type T allele
produced a single 121 bp fragment and the polymorphic
G allele produced two fragments of 104- and 17 bp. The
product was analyzed on 2% agarose gel stained with
ethidium bromide (Figure 1). The nucleotide change
and the three genotypes can be visualized on sequences
analysis that were shown on Figure 2.
Statistical methods
The genetic frequency and association analysis between
the comparison groups was performed with UNPHASED
v.3.121 [41], whereas association analysis between these
groups and risk factor (use of contraceptive) was con-
ducted with SNPStats [42]. All the tests were two-tailed
and the level of significance for all of the statistical results
was set at p < 0.05.Ethical approval
This work has been approved by Ethics Committee on
Human Research – Hospital Complex HUOC/PROCAPE
(HUOC/PROCAPE 64/2010).
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